Data shows three years of continuous treatment with Leqembi reduces cognitive decline in patients with early-stage Alzheimer’s disease

Results from the Phase 3 Clarity AD study showed that Leqembi reduced cognitive decline by -0.95 on the Clinical Dementia Rating Box Total compared to expected cognitive decline in the untreated group.